Scott Kinlay։ Cancer and Adverse Outcomes Over 5 Years After Coronary Stenting and Optimal DAPT Duration
Scott Kinlay, Chief of Cardiology at VA Boston Healthcare System and Associate Professor of Medicine at Harvard Medical School, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Just published: Ramael Ohiomoba and Edwin Mandieka’s paper examines the relationship of cancer to adverse outcomes over 5 years after coronary stenting, as well as the optimal duration DAPT.
Key findings were that cancer patients have higher rates of myocardial infarction and major bleeding after PCI compared to non-cancer patients. The analysis also supports a similar duration of DAPT after PCI in cancer patients as non-cancer patients.”
Title: Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention
Authors: Ramael Ohiomoba, Edwin Mandieka, Melissa M Young, David R Gagnon, Scott Kinlay
Read the Full Article on European Heart Journal.
Stay updated on all scientific advances with Hemostasis Today.
-
May 10, 2026, 11:57Mostafa Meshref: Find Our Research Contributions at ESOC 2026
-
May 10, 2026, 11:39Ruisheng Su: Stroke Timer Is an Early Accept at MICCAI 2026
-
May 10, 2026, 11:24Ali Ahmadi: The Immune Landscape After Ischemic Stroke and How to Advance Toward Effective Therapeutic Strategies
-
May 10, 2026, 11:05Yusra Iqbal: The Clinical Spectrum of Platelet Disorders
-
May 10, 2026, 08:42Muhammad Asim: The Clinical Value of Cord Blood in Neonatal Practice
-
May 10, 2026, 08:22Annie Bauzon: Why Every MLS Should Understand Blood Products
-
May 10, 2026, 08:11Waleed Zia: The Balance Between Bleeding and Thrombosis
-
May 10, 2026, 07:34Seema Dawood: Decoding Giant Platelets in Coagulation and Bone Marrow Disorders
-
May 10, 2026, 00:50Abdulla A. Damluji: Pulsed Field Ablation Delivers a New Standard for Persistent AF